CD34 and acute myeloid leukemia: FLT3-ITD+ AML cells showed greater sensitivity to the pan-RAS inhibitor than either CD34+ cells, or an AML with wild-type FLT3 plus a MOZ::TIF rearrangement (Figure 6F).